Inflammatory and Genetic Predictors of Cognitive and Emotional Recovery After Critical Illness

To characterize inflammatory and anti-inflammatory response phenotypes using transcriptomic and biomarker data

To characterize pathological aging mechanisims with APOE genotype

Measured using the Richmond Sedation-Agitation Scale (RASS) Score range: from -5 (unarousable) to +5 (agitated)

Assessed using the Sequential Organ Failure Assessment (SOFA) questionnaire

Score range: 0-24; 0-6: Mild organ dysfunction 7-9: Moderate severity 10-12: Significant organ dysfunction 13+: Severe illness with substantially increased mortality risk

Measured using the Charlson Comorbidity Index (CCI)

0-1 point: Low comorbidity (absence of comorbidities or only very mild diseases).

2-3 points: Moderate to low comorbidity. 4 points or more: Severe comorbidity or high risk.

Assessed using the Rockwood Clinical Frailty Scale (CFS)

Score range from 0 to 9; 1-3: Fit / Non-frail 4: Vulnerable / Very mild frailty 5: Mild frailty 6: Moderate frailty 7-8: Severe to very severe frailty 9: Terminal illness

Assessed using the Confusion Assessment Method for the ICU (CAM-ICU) Recorded as Yes/No

Categorised as:

• no mechanical ventilation
• invasive mechanical ventilation
• high-flow oxygen therapy
• non-invasive mechanical ventilation

Type of sedative agents administered:

• none
• propofol
• midazolam
• remifentanil
• dexmedetomidine

Recorded as Yes/No

Assessed using the Montreal Cognitive Assessment (MoCA) Score range: 0-30

Interpretation:

26-30 Normal cognitive function 18-25 Mild cognitive impairment (possible) 10-17 Moderate cognitive impairment <10 Severe cognitive impairment

Assessed using Digit Span Forward and Backward (WAIS-IV); Scaled score range: 1-19. Higher scores indicate better performance; scores <8 suggest impairment.

Assessed using the Rey Auditory Verbal Learning Test (RAVLT); Total score range recall varies (typically 0-75). Higher scores indicate better verbal learning and memory.

• Assessed using Coding (WAIS-IV); Scaled score range 1-19. Higher scores indicate better processing speed; scores <8 suggest impairment.
• Assessed using the Symbol Digit Modalities Test (SDMT); Higher scores indicate better processing speed.

Assessed using the Trail Making Test Part B (TMT-B); measured in seconds. Lower completion time indicates better performance.

Assessed using the Stroop Colour and Word Test. Higher scores indicate greater impairment in inhibitory control.

Assessed using the Phonetic Fluency (FAS) Test; measured as the number of words generated. Higher scores indicate better verbal fluency.

Assessed using the Patient Health Questionnaire-9 (PHQ-9).

Score range 0-27;

0-4: None 5-9: Mild 10-14: Moderate 15-19: Moderately severe 20-27: Severe

Assessed using the Generalized Anxiety Disorder-7 (GAD-7).

Score range 0-21;

0-4: Minimal 5-9: Mild 10-14: Moderate 15-21: Severe

Assessed using the Treatment-Outcome Posttraumatic Stress Disorder Scale (TOP-8) Score range 0-32. Higher scores indicate greater PTSD symptom severity.

Assessed using the Perceived Deficits Questionnaire (PDQ-D5). Score range 0-20. Higher scores indicate greater perceived cognitive impairment.

Assessed using the FACIT Fatigue Scale (FACIT-F). Score range 0-52. Lower scores indicate greater fatigue, while higher scores indicate less fatigue.

Assessed using the Visual Analogue Scale (VAS-10).

Score range 0-10;

0: No symptoms 1-3: Mild 4-6: Moderate 7-10: Severe

Assessed using the Visual Analogue Scale (VAS-10).

Score range 0-10;

0: No symptoms 1-3: Mild 4-6: Moderate 7-10: Severe

Assessed using the Pittsburgh Sleep Quality Index (PSQI). Score range 0-21. Scores >5 indicate poor sleep quality.

Assessed using the Posttraumatic Growth Inventory (PTGI). Score range 0-105. Higher scores indicate greater post-traumatic growth.

Assessed using the 12-Item Short Form Health Survey (SF-12). Score range 0-100. Higher scores indicate better health-related quality of life.